Researchers computationally find the needle in a haystack to treat rare diseases

March 13, 2018, Louisiana State University
Chemotherapeutic vandetanib bound to its main target Protein Tyrosine Kinase 6 (PTK6) in purple, which is involved in many cancers including gastrointestinal tumors and ovarian cancers. By modeling vandetanib and PTK6 complex, researchers at LSU found that the KRAS protein to also contain a similar drug-binding site and therefore to be a good match for the same drug. The computer-generated model of KRAS in gold with vandetanib depicts the predicted interaction. Credit: Misagh Naderi, LSU

One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition. Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.

"Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled 'orphan diseases.' We developed a way to computationally find matches between rare protein structures and functions and existing interactions that can help treat patients with some of these orphan diseases," said Misagh Naderi, one of the paper's lead authors and a doctoral candidate in the LSU Department of Biological Sciences.

This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.

KRAS protein is known to be involved in heart and autoimmune diseases as well as many cancers of the blood, skin, lung, and colon. The discovery made by the Computational Systems Biology Group at LSU can lead to the repurposing of known FDA-approved drugs to treat rare conditions also known as "orphan diseases" that are currently untreated. Credit: Misagh Naderi, LSU

"In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson's disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease," said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.

To systematize drug repurposing, Naderi, co-author Rajiv Gandhi Govindaraj and colleagues combined eMatchSite, a software developed by the same group with virtual screening to match FDA approved drugs and proteins that are involved in . LSU super computers allows them to test millions of possibilities that will cost billions of dollars to test in the lab.

Explore further: Researchers find how a drug for osteoporosis is effective to treat a rare disease

Related Stories

FDA drug approvals reached 18-year high in 2014

January 2, 2015

The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.

Recommended for you

Scientists examine variations in a cell's protein factory

September 19, 2018

You can think of a cell in your body like a miniature factory, creating a final product called proteins, which carry out various tasks and functions. In this cellular factory, genes control the series of sequential steps ...

Scientists crack genetic code of cane toad

September 19, 2018

A group of scientists from UNSW Sydney, the University of Sydney, Deakin University, Portugal and Brazil have unlocked the DNA of the cane toad, a poisonous amphibian that is a threat to many native Australian species. The ...

Why some animals still have a penis bone

September 19, 2018

A team of researchers affiliated with several institutions in the U.K. has found a possible explanation for why some animals still have a penis bone—"prolonged intromission." In their paper published in Proceedings of the ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

humy
not rated yet Mar 13, 2018
"...it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition...."

This shows the great humanitarian need for certain no-profittable state-sponsored, i.e. tax-payer funded, science research, at the very least for medical science research.
Some right-wing extremists would disagree.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.